Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study-Reference-Cited by-同舟云学术

Prostate cancer screening in men aged 50–69 years (STHLM3): a prospective population-based diagnostic study

Published:2015-12 Issue:16 Volume:16 Page:1667-1676
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Grönberg Henrik,Adolfsson Jan,Aly Markus,Nordström Tobias,Wiklund Peter,Brandberg Yvonne,Thompson James,Wiklund Fredrik,Lindberg Johan,Clements Mark,Egevad Lars,Eklund Martin

Publisher

Elsevier BV

Subject

Oncology

Reference35 articles.

1. The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines;Etzioni;Cancer,2012

2. Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up;Schroder;Lancet,2014

3. Overdiagnosis and overtreatment of prostate cancer;Loeb;Eur Urol,2014

4. Screening for prostate cancer: US Preventive Services Task Force recommendation statement;Moyer;Annals Intern Med,2012

5. Systematic review of complications of prostate biopsy;Loeb;Eur Urol,2013

Cited by 326 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spatio-temporal variation in prostate cancer testing in Stockholm: A population-based study;PLOS ONE;2024-08-15

2. Tailoring biopsy strategy in the MRI-fusion prostate biopsy era: systematic, targeted or neither?;BMC Urology;2024-08-07

3. The association between patient characteristics, psychological distress, and coping in the diagnostic phase of prostate cancer – A cross-sectional multicenter study;European Journal of Oncology Nursing;2024-08

4. Cost Analysis of Prostate Cancer Care Using a Biomarker-enhanced Diagnostic Strategy with Stockholm3;European Urology Open Science;2024-08

5. External Validation of Stockholm3 in a Retrospective German Clinical Cohort;European Urology Focus;2024-08